HRP20030870B1 - Aripiprazole oral solution - Google Patents

Aripiprazole oral solution

Info

Publication number: HRP20030870B1
Authority: HR; Croatia
Prior art keywords: acid; oral solution; aripiprazole; solution; aripiprazole oral
Prior art date: 2001-04-25

Application number

HR20030870A

Other languages

English (en)

Croatian (hr)

Inventor

Parab Prakash

Chou Joyce

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2002-04-24

Publication date

2011-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20030870(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-24 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2004-06-30 Publication of HRP20030870A2 publication Critical patent/HRP20030870A2/hr

2011-10-31 Publication of HRP20030870B1 publication Critical patent/HRP20030870B1/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Psychiatry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HR20030870A 2001-04-25 2002-04-24 Aripiprazole oral solution HRP20030870B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28671801P	2001-04-25	2001-04-25
PCT/US2002/013048 WO2002085366A1 (en)	2001-04-25	2002-04-24	Aripiprazole oral solution

Publications (2)

Publication Number	Publication Date
HRP20030870A2 HRP20030870A2 (en)	2004-06-30
HRP20030870B1 true HRP20030870B1 (en)	2011-10-31

Family

ID=23099862

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20030870A HRP20030870B1 (en)	2001-04-25	2002-04-24	Aripiprazole oral solution

Country Status (36)

Country	Link
US (1)	US6977257B2 (is)
EP (2)	EP2436384B2 (is)
JP (1)	JP4401077B2 (is)
KR (1)	KR100909329B1 (is)
CN (1)	CN1512884B (is)
AR (1)	AR033168A1 (is)
AT (1)	ATE537831T1 (is)
AU (1)	AU2002254722B2 (is)
BG (1)	BG66177B1 (is)
BR (1)	BR0208986A (is)
CA (1)	CA2445276C (is)
CY (1)	CY1112606T1 (is)
CZ (1)	CZ306181B6 (is)
DK (1)	DK1381367T3 (is)
EE (1)	EE05581B1 (is)
ES (1)	ES2377855T3 (is)
GE (1)	GEP20053602B (is)
HR (1)	HRP20030870B1 (is)
HU (1)	HU230456B1 (is)
IL (2)	IL158202A0 (is)
IS (1)	IS2863B (is)
MX (1)	MXPA03009728A (is)
MY (1)	MY129350A (is)
NO (1)	NO324606B1 (is)
NZ (1)	NZ528550A (is)
PE (1)	PE20021086A1 (is)
PL (1)	PL206882B1 (is)
PT (1)	PT1381367E (is)
RS (1)	RS52082B (is)
RU (1)	RU2295960C2 (is)
SK (1)	SK287948B6 (is)
TW (1)	TWI337865B (is)
UA (1)	UA76144C2 (is)
UY (1)	UY27273A1 (is)
WO (1)	WO2002085366A1 (is)
ZA (1)	ZA200307797B (is)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6770478B2 (en) *	2000-02-10	2004-08-03	The Regents Of The University Of California	Erythrocytic cells and method for preserving cells
HRP20050149B1 (hr) *	2002-08-20	2014-09-12	Otsuka Pharmaceutical Co., Ltd.	Formulacija aripiprazol kompleksa i postupak
WO2005035000A1 (en) *	2003-10-08	2005-04-21	Mallinckrodt Inc.	Methylphenidate solution and associated methods of administration and production
PT1675573E (pt) *	2003-10-23	2008-12-30	Otsuka Pharma Co Ltd	Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação
JP4994043B2 (ja) *	2004-01-21	2012-08-08	エランコ・アニマル・ヘルス・アイルランド・リミテッド	ミトラタピデ経口用溶液
EP1933814A2 (en)	2005-09-15	2008-06-25	Elan Pharma International Limited	Nanoparticulate aripiprazole formulations
CN101351193A (zh) *	2006-01-05	2009-01-21	特瓦制药工业有限公司	阿立哌唑的干法制剂
DK1808164T3 (da) *	2006-01-05	2009-04-20	Teva Pharma	Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
JP4892264B2 (ja) *	2006-03-30	2012-03-07	高田製薬株式会社	リスペリドン水性液剤
WO2007144874A1 (en)	2006-06-12	2007-12-21	Hadasit Medical Research Services And Development Ltd.	Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
GB0618879D0 (en)	2006-09-26	2006-11-01	Zysis Ltd	Pharmaceutical compositions
JP4879349B2 (ja) *	2007-07-31	2012-02-22	大塚製薬株式会社	アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
WO2009042166A1 (en) *	2007-09-25	2009-04-02	Panacos Pharmaceuticals, Inc.	Liquid bevirimat dosage forms for oral administration
GB2456183A (en) *	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US8716263B2 (en)	2008-12-23	2014-05-06	Gilead Pharmasset Llc	Synthesis of purine nucleosides
EA201100851A1 (ru)	2008-12-23	2012-04-30	Фармассет, Инк.	Аналоги нуклеозидов
EA019341B1 (ru)	2008-12-23	2014-02-28	Джилид Фармассет, Ллс.	Фосфорамидаты нуклеозидов
TWI576352B (zh)	2009-05-20	2017-04-01	基利法瑪席特有限責任公司	核苷磷醯胺
US8815261B2 (en) *	2009-06-19	2014-08-26	Medrx Co., Ltd.	Composition for external application comprising aripiprazole and organic acid as active ingredients
TR201000948A1 (tr)	2010-02-09	2011-08-22	Sanovel İlaç San.Ve Ti̇c.A.Ş.	Aripiprazol formülasyonları.
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
MX2012011171A (es)	2010-03-31	2013-02-01	Gilead Pharmasset Llc	Fosforamidatos de nucleosido.
UY33312A (es)	2010-03-31	2011-10-31	Pharmasset Inc	Fosforamidato de nucleosido de purina
JP6069215B2 (ja)	2010-11-30	2017-02-01	ギリアドファーマセットエルエルシー	化合物
HRP20240285T1 (hr)	2011-03-18	2024-05-24	Alkermes Pharma Ireland Limited	Farmaceutski pripravci koji sadrže sorbitan estere
JO3410B1 (ar)	2011-06-07	2019-10-20	Otsuka Pharma Co Ltd	تركيبة أريبيبرازول مجفف بالتبريد
JP6034377B2 (ja) *	2011-06-27	2016-11-30	シャンハイチョンシファーマシューティカルコーポレイション	アリピプラゾール医薬製剤及びその調製方法
CN102846616B (zh) *	2011-06-27	2015-05-06	上海中西制药有限公司	一种阿立哌唑制剂及其制备方法
AR088372A1 (es) *	2011-10-19	2014-05-28	Otsuka Pharma Co Ltd	Solucion para administracion oral
EP2827866B1 (en)	2012-03-19	2023-05-03	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising benzyl alcohol
ES2764383T3 (es)	2012-03-19	2020-06-03	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que comprenden ésteres de glicerol
AU2013235519C1 (en)	2012-03-19	2018-04-26	Alkermes Pharma Ireland Limited	Pharmaaceutical compositions comprising fatty acid esters
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن
JP5341282B1 (ja) *	2012-06-29	2013-11-13	丸石製薬株式会社	アリピプラゾールの経口医薬製剤
US20150174247A1 (en)	2012-06-29	2015-06-25	Maruishi Pharmaceutical Co., Ltd.	Oral pharmaceutical preparation of aripiprazole
KR101571670B1 (ko) *	2012-08-08	2015-11-25	주식회사 씨엠지제약	아리피프라졸을 포함하는 경구용 속용 필름 제제
ES2792149T3 (es)	2012-09-19	2020-11-10	Alkermes Pharma Ireland Ltd	Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
AU2013323435C1 (en) *	2012-09-26	2018-04-12	Bristol-Myers Squibb Holdings Ireland Unlimited Company	Apixaban liquid formulations
US8568747B1 (en)	2012-10-05	2013-10-29	Silvergate Pharmaceuticals, Inc.	Enalapril compositions
WO2014059363A1 (en) *	2012-10-11	2014-04-17	Antrim Pharmaceuticals Llc	Oral solution formulations of aripiprazole
PL2908859T3 (pl) *	2012-10-16	2017-10-31	Arven Ilac Sanayi Ve Ticaret As	Formulacje arypiprazolu
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
JP6203682B2 (ja) *	2013-07-10	2017-09-27	共和薬品工業株式会社	アリピプラゾール含有水性液剤
CN103393594A (zh) *	2013-08-22	2013-11-20	万特制药(海南)有限公司	一种新的阿立哌唑的制剂组合物
MX376057B (es)	2014-03-20	2025-03-07	Alkermes Pharma Ireland Ltd	Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
WO2016189504A1 (en) *	2015-05-28	2016-12-01	Leiutis Pharmaceuticals Pvt Ltd	Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) *	2015-06-12	2016-12-07	高田製薬株式会社	アリピプラゾール含有内用液剤
WO2017025930A1 (en)	2015-08-12	2017-02-16	Ftf Pharma Private Limited	Oral solution of aripiprazole
US9463183B1 (en)	2015-10-30	2016-10-11	Silvergate Pharmaceuticals, Inc.	Lisinopril formulations
US9669008B1 (en)	2016-03-18	2017-06-06	Silvergate Pharmaceuticals, Inc.	Enalapril formulations
CN108434146A (zh) *	2017-02-16	2018-08-24	天津国际生物医药联合研究院	一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) *	2017-09-15	2019-03-22	万特制药(海南)有限公司	阿立哌唑口服溶液及其制备方法
AU2019230014B2 (en)	2018-03-05	2024-11-28	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
CN112666267B (zh) *	2019-10-15	2023-09-26	上海上药中西制药有限公司	一种阿立哌唑药品有关物质的检测方法
JP2023173950A (ja) *	2022-05-27	2023-12-07	同仁医薬化工株式会社	経口液剤

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU843739A3 (ru)	1978-02-17	1981-06-30	Карл Томэ Гмбх (Фирма)	Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en)	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
PH17194A (en) *	1980-03-06	1984-06-19	Otsuka Pharma Co Ltd	Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja)	1982-09-29	1984-04-05	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体−シクロデキストリン包接化合物
DE3933027A1 (de) *	1989-09-29	1991-04-11	Schering Ag	Kombinationspraeparat mit antithrombotischer wirkung
JP3265680B2 (ja) *	1992-03-12	2002-03-11	大正製薬株式会社	経口製剤用組成物
US5457099A (en)	1992-07-02	1995-10-10	Sawai Pharmaceutical Co., Ltd.	Carbostyril derivatives and antiallergic agent
TW254855B (is)	1993-07-28	1995-08-21	Otsuka Pharma Co Ltd
EP0971746A1 (en) *	1997-03-31	2000-01-19	Johnson & Johnson Consumer Companies, Inc.	Solvent system for enhanced penetration of pharmaceutical compounds
US20030077227A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
CA2342844A1 (en) *	1998-09-03	2000-03-16	Robert D. Kross	Freeze-resistant topical germicides and methods related thereto
CA2311734C (en) *	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
WO2003030868A1 (en) *	2001-10-09	2003-04-17	Bristol-Myers Squibb Company	Flashmelt oral dosage formulation

2002
- 2002-03-28 MY MYPI20021124A patent/MY129350A/en unknown
- 2002-04-15 AR ARP020101366A patent/AR033168A1/es unknown
- 2002-04-19 TW TW091108139A patent/TWI337865B/zh not_active IP Right Cessation
- 2002-04-24 AT AT02723964T patent/ATE537831T1/de active
- 2002-04-24 EP EP11190103.9A patent/EP2436384B2/en not_active Expired - Lifetime
- 2002-04-24 PT PT02723964T patent/PT1381367E/pt unknown
- 2002-04-24 AU AU2002254722A patent/AU2002254722B2/en not_active Expired
- 2002-04-24 WO PCT/US2002/013048 patent/WO2002085366A1/en not_active Ceased
- 2002-04-24 NZ NZ528550A patent/NZ528550A/en not_active IP Right Cessation
- 2002-04-24 HR HR20030870A patent/HRP20030870B1/xx not_active IP Right Cessation
- 2002-04-24 US US10/131,304 patent/US6977257B2/en not_active Expired - Lifetime
- 2002-04-24 GE GE5332A patent/GEP20053602B/en unknown
- 2002-04-24 RS YU84703A patent/RS52082B/sr unknown
- 2002-04-24 EE EEP200300523A patent/EE05581B1/xx not_active IP Right Cessation
- 2002-04-24 PL PL364666A patent/PL206882B1/pl unknown
- 2002-04-24 BR BR0208986-6A patent/BR0208986A/pt active Search and Examination
- 2002-04-24 ES ES02723964T patent/ES2377855T3/es not_active Expired - Lifetime
- 2002-04-24 CA CA002445276A patent/CA2445276C/en not_active Expired - Fee Related
- 2002-04-24 SK SK1264-2003A patent/SK287948B6/sk not_active IP Right Cessation
- 2002-04-24 MX MXPA03009728A patent/MXPA03009728A/es active IP Right Grant
- 2002-04-24 CN CN028112148A patent/CN1512884B/zh not_active Ceased
- 2002-04-24 RU RU2003132426/15A patent/RU2295960C2/ru not_active IP Right Cessation
- 2002-04-24 JP JP2002582939A patent/JP4401077B2/ja not_active Expired - Lifetime
- 2002-04-24 EP EP02723964A patent/EP1381367B1/en not_active Expired - Lifetime
- 2002-04-24 UY UY27273A patent/UY27273A1/es not_active Application Discontinuation
- 2002-04-24 HU HU0303946A patent/HU230456B1/hu not_active IP Right Cessation
- 2002-04-24 DK DK02723964.9T patent/DK1381367T3/da active
- 2002-04-24 KR KR1020037013943A patent/KR100909329B1/ko not_active Expired - Lifetime
- 2002-04-24 UA UA20031110599A patent/UA76144C2/uk unknown
- 2002-04-24 CZ CZ2003-2821A patent/CZ306181B6/cs not_active IP Right Cessation
- 2002-04-24 IL IL15820202A patent/IL158202A0/xx active IP Right Grant
- 2002-04-25 PE PE2002000346A patent/PE20021086A1/es not_active Application Discontinuation
2003
- 2003-10-01 IL IL158202A patent/IL158202A/en not_active IP Right Cessation
- 2003-10-01 BG BG108216A patent/BG66177B1/bg unknown
- 2003-10-06 ZA ZA200307797A patent/ZA200307797B/en unknown
- 2003-10-14 IS IS6994A patent/IS2863B/is unknown
- 2003-10-21 NO NO20034705A patent/NO324606B1/no not_active IP Right Cessation
2012
- 2012-03-14 CY CY20121100273T patent/CY1112606T1/el unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives

Also Published As

Publication number	Publication date
ES2377855T3 (es)	2012-04-02
PL364666A1 (en)	2004-12-13
HK1058316A1 (en)	2004-05-14
RU2295960C2 (ru)	2007-03-27
EP2436384A2 (en)	2012-04-04
RU2003132426A (ru)	2005-04-20
EP2436384A3 (en)	2012-09-19
EE05581B1 (et)	2012-10-15
EP1381367B1 (en)	2011-12-21
CN1512884A (zh)	2004-07-14
GEP20053602B (en)	2005-08-10
NO20034705L (no)	2003-11-28
KR100909329B1 (ko)	2009-07-24
IS6994A (is)	2003-10-14
JP2004532225A (ja)	2004-10-21
ZA200307797B (en)	2004-10-06
CA2445276A1 (en)	2002-10-31
AU2002254722B2 (en)	2006-11-09
CZ306181B6 (cs)	2016-09-14
CZ20032821A3 (cs)	2004-09-15
BG108216A (bg)	2004-12-30
RS52082B (sr)	2012-06-30
NZ528550A (en)	2005-03-24
EP1381367A1 (en)	2004-01-21
HRP20030870A2 (en)	2004-06-30
AR033168A1 (es)	2003-12-03
WO2002085366A1 (en)	2002-10-31
US20020193438A1 (en)	2002-12-19
HUP0303946A3 (en)	2005-06-28
DK1381367T3 (da)	2012-04-10
BG66177B1 (bg)	2011-11-30
PE20021086A1 (es)	2002-12-14
HU230456B1 (hu)	2016-07-28
ATE537831T1 (de)	2012-01-15
PL206882B1 (pl)	2010-10-29
HUP0303946A2 (hu)	2004-04-28
CY1112606T1 (el)	2016-02-10
NO324606B1 (no)	2007-11-26
EP2436384B1 (en)	2015-06-10
EP1381367A4 (en)	2009-07-01
MXPA03009728A (es)	2004-01-29
KR20030096332A (ko)	2003-12-24
EP2436384B2 (en)	2018-05-23
BR0208986A (pt)	2004-04-20
NO20034705D0 (no)	2003-10-21
CA2445276C (en)	2009-10-13
JP4401077B2 (ja)	2010-01-20
MY129350A (en)	2007-03-30
IL158202A (en)	2008-04-13
TWI337865B (en)	2011-03-01
HK1168792A1 (en)	2013-01-11
IL158202A0 (en)	2004-05-12
CN1512884B (zh)	2010-05-26
EE200300523A (et)	2004-02-16
UA76144C2 (uk)	2006-07-17
PT1381367E (pt)	2012-03-01
US6977257B2 (en)	2005-12-20
YU84703A (sh)	2006-08-17
SK287948B6 (sk)	2012-06-04
UY27273A1 (es)	2002-11-29
SK12642003A3 (sk)	2004-07-07
IS2863B (is)	2013-12-15

Publication	Publication Date	Title
HRP20030870B1 (en)	2011-10-31	Aripiprazole oral solution
HRP20010332B1 (hr)	2011-01-31	Farmaceutski pripravak moksifloksacina
DZ2964A1 (fr)	2004-03-15	Diphénylurées substituées nouvelles, et compositions pharmaceutiques les contenant.
EP1028715A4 (en)	2001-10-10	FORMULATION FOR NASAL SUPPORT AND METHOD OF USE THEREOF
MY114388A (en)	2002-10-31	Multiple unit pharmaceutical preparation
ATE235893T1 (de)	2003-04-15	Orale zubereitung enthaltend zonula occludens toxin und einen biologisch aktiven wirkstoff sowie deren verwendung
EP1078628A3 (en)	2003-03-19	Multiple unit tableted dosage form
WO2005045689A8 (en)	2007-06-28	Methods and systems for network coordination
EE04275B1 (et)	2004-04-15	Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid
ME00578A (en)	2011-12-20	Use of gastrointestinal lipase inhibitors
BR0213379A (pt)	2005-02-01	Formulação resistente a derramamento de mascaramento de gosto
HRP20030050B1 (en)	2011-07-31	Sustained-release preparations of quinolone antibiotics and method for preparation thereof
ATE304013T1 (de)	2005-09-15	1,2,3-substituierte indolizinderivate, fgf inhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
IS6956A (is)	2003-09-15	Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
DK1104289T3 (da)	2006-05-15	Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
NO20026212L (no)	2003-02-06	Forbindelse for medikamentavleveringssystem og fremgangsmåte for fremstilling av forbindelsen
HRP20010878B1 (en)	2007-03-31	Ziprasidone suspension
TW200420557A (en)	2004-10-16	Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
DE60131085D1 (de)	2007-12-06	Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika
DE69711633D1 (de)	2002-05-08	Stabile derivate von ubiquinol, verfahren zu ihrer herstellung und ihre pharmazeutische anwendung
DE3880953D1 (de)	1993-06-17	Chinolinderivate, verfahren zur herstellung davon und diese enthaltendes antibakterielles mittel.
TR199903065T2 (xx)	2000-09-21	Oral uygulamaya y�nelik rapamisin form�lasyonlar�.
DE69927997D1 (de)	2005-12-01	Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
DE69011046D1 (de)	1994-09-01	Pyridinderivate, Verfahren zur Herstellung und pharmazeutische Zusammensetzungen.
HRP20000703B1 (hr)	2009-11-30	Stabilni pripravci koji sadrže levosimendan i alginsku kiselinu

Legal Events

Date	Code	Title	Description
2004-06-30	A1OB	Publication of a patent application
2004-12-20	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2011-10-31	B1PR	Patent granted
2014-06-11	PNAN	Change of the applicant name, address/residence	Owner name: BRISTOL-MYERS SQUIBB COMPANY, US
2014-06-11	PPPP	Transfer of rights	Owner name: OTSUKA PHARMACEUTICAL CO., LTD., JP
2018-04-10	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20180410 Year of fee payment: 17
2019-11-05	PBON	Lapse due to non-payment of renewal fee	Effective date: 20190424